GleamWall
中文EN

PPCB Propanc Biopharma, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1517681 · Fiscal year ends 06/30

Financial factors as of 2026-09-30 (2026Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY64.3%
TTM EPS YoY115.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-211.0%
ROA-159.8%
ROIC (approx.)-168.8%
Asset turnover—

Leverage & solvency

Liabilities / assets31.5%
Debt / equity0.00x
Current ratio2.47x
Interest coverage-154.29x

Cash quality & payout

Operating cash flow / net income0.25x
Accruals ratio-119.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20262026-06-30FY20252025-06-30
Income statement
Revenue——
R&D expense$625,477$223,721
SG&A expense$670,607$108,950
Operating income-$18.19M-$57.28M
Interest expense$430,539$563,757
Pretax income-$18.86M-$58.92M
Net income-$18.86M-$58.92M
EBITDA-$18.18M—
EPS (basic)-17.62-371.22
EPS (diluted)-17.62-371.22
Weighted avg. shares (diluted)1.12M158,727
Balance sheet
Cash & equivalents$832,006$12,088
Current assets$8.54M$8.35M
PP&E, net$3,915—
Total assets$12.78M$19.63M
Current liabilities$3.35M$5.58M
Long-term debt—$537,921
Total debt—$537,921
Total liabilities$3.38M$5.73M
Shareholders' equity$9.40M$13.91M
Net debt—$525,833
Shares outstanding331,083464,471
Cash flow statement
Operating cash flow-$5.68M-$405,168
Capital expenditure$4,933—
Free cash flow-$5.69M—
Investing cash flow-$4,933—
Financing cash flow$6.46M$490,756
Depreciation & amortization$997—
Stock-based compensation$8.50M$4.62M

Free plan shows the latest 2 periods; Pro shows all 18 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.